Critical Comparison: Cardio Diagnostics (NASDAQ:CDIO) vs. BG Medicine (OTCMKTS:BGMD)

BG Medicine (OTCMKTS:BGMD) and Cardio Diagnostics (NASDAQ:CDIO) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, earnings, dividends and institutional ownership.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for BG Medicine and Cardio Diagnostics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BG Medicine	0	0	0	0	0.00
Cardio Diagnostics	0	0	1	0	3.00

Cardio Diagnostics has a consensus target price of $2.00, suggesting a potential upside of 371.36%. Given Cardio Diagnostics’ stronger consensus rating and higher probable upside, analysts plainly believe Cardio Diagnostics is more favorable than BG Medicine.

Earnings and Valuation

This table compares BG Medicine and Cardio Diagnostics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BG Medicine	N/A	N/A	N/A	N/A	N/A
Cardio Diagnostics	$35,688.00	619.96	-$8.38 million	N/A	N/A

BG Medicine has higher earnings, but lower revenue than Cardio Diagnostics.

Insider and Institutional Ownership

8.1% of Cardio Diagnostics shares are held by institutional investors. 6.5% of BG Medicine shares are held by company insiders. Comparatively, 22.3% of Cardio Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares BG Medicine and Cardio Diagnostics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BG Medicine	N/A	N/A	N/A
Cardio Diagnostics	-22,732.03%	-258.85%	-191.20%

Risk & Volatility

BG Medicine has a beta of 1.13, meaning that its share price is 13% more volatile than the S&P 500. Comparatively, Cardio Diagnostics has a beta of 3.61, meaning that its share price is 261% more volatile than the S&P 500.

Summary

Cardio Diagnostics beats BG Medicine on 7 of the 10 factors compared between the two stocks.

About BG Medicine

BG Medicine, Inc. engages in the development and commercialization of diagnostic products used to guide the patients suffering from heart failure and related disorders in the United States. The company offers BGM Galectin-3 Test, an in vitro diagnostic device that measures galectin-3 in serum or plasma by enzyme linked immunosorbent assay on a microtiter plate platform; and CardioSCORE Test, a multi-analyte biomarker-based blood test used for the assessment of near-term risk of atherothrombotic cardiovascular events, such as heart attack and ischemic stroke. It has license, development, and commercialization agreements with Abbott Laboratories, bioMérieux SA, Siemens Healthcare Diagnostics Inc., and Alere Inc. for the automated instrument versions of galectin-3 test; and a strategic collaboration with Abbott Laboratories to develop and commercialize galectin-3 assay kits, and related control kits and calibrators. The company was formerly known as Beyond Genomics, Inc. and changed its name to BG Medicine, Inc. in October 2004. BG Medicine, Inc. was founded in 2000 and is headquartered in Waltham, Massachusetts.

About Cardio Diagnostics

Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.